chrisvoncsefalvay/vaers-outcomes huggingface dataset:
answered yes to experiencing a side effect; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (answered yes to experiencing a side effect) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (answered yes to experiencing a side effect). At the time of the report, VACCINATION COMPLICATION (answered yes to experiencing a side effect) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications reported.  No treatment information was provided.
mixed doses Pfizer and Moderna/My first vaccine was Pfizer, my second was Moderna; chills; fever 103.2; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (mixed doses Pfizer and Moderna/My first vaccine was Pfizer, my second was Moderna), CHILLS (chills) and PYREXIA (fever 103.2) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (mixed doses Pfizer and Moderna/My first vaccine was Pfizer, my second was Moderna), CHILLS (chills) and PYREXIA (fever 103.2). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (mixed doses Pfizer and Moderna/My first vaccine was Pfizer, my second was Moderna), CHILLS (chills) and PYREXIA (fever 103.2) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
approx 1wk p/vax deltoid region of arm started to collapse & proceeded to get worse over a period of months;saw neurologist who put pt on vit B-6 & mult vit;also given B-12 inj; rx for diflucan;site sometimes aches;
I had one in my 20s it made me so sick; Initial information received on 11-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via social media.  This case is linked to case 2020SA294157.  This case involves an unknown age patient who reported had one in her/his 20s it made he/she so sick (illness), while he/she received vaccine INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE [FLUZONE].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose  dose of suspect INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE lot number not reported in unknown administration site.  On an unknown date, the patient developed a non-serious it was reported that patient had one in her/his 20s it made he/she so sick(illness) (Unknown latency) following the administration of INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE.  Final diagnosis was patient had one in her/his 20s it made he/she so sick.   No relevant laboratory details were provided.  It was not reported if the patient received a corrective treatment.  Outcome of the event was unknown at the time of reporting.  There will be no information available on the batch number for this case.
Patient came to the vaccination center to receive the second dose of her Pfizer primary series vaccine. The nurse administered a Pfizer bivalent booster dose in error. The patient's immunization record had two doses of primary vaccine that were uploaded by the Immunization Information Registry in error. These two doses were actually received by the patient's twin sister. Patient was informed of the medication error, and how to contact the Immunization Information Registry to correct the documentation error. Patient was also advised that per CDC guidelines, the patient did not need to repeat their second primary dose vaccine. The patient should return to the vaccination center to receive a second bivalent booster dose two months after their last covid vaccine dose.
Approximately 5 minutes after dose was administered  reported loss of vision for 3 minutes and then vision returned.  He denied feeling light headed or dizzy.  Blood pressure was 119/62 from left arm.  No report of double vision.
I had a mild fever; I had no energy whatsoever; and I hurt like crazy/  I was in a lot of pain; I would have gone to the hospital because it felt so bad; its felt like the flu only much, much worse it only lasted about 36 hours altogether; Its very uncomfortable; Headache; just the pain, muscle pain; I felt so wretched; This is a spontaneous report from a contactable consumer (patient).  A 75-years-old female patient received third dose (booster) of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number: FE3592 and expiry date was not reported), via an unspecified route of administration, in Arm Left, on 25Sep2021 (age at vaccination: 75 years), as dose 3 (booster), single dose for COVID-19 immunization. The patient's medical history included Grave's disease and anxiety. Concomitant medications included thyroid (ARMOUR THYROID), acetylsalicylic acid (ASPIRINE), and antacid. The patient reported that she had ache, her body aches, she had a mild fever. She had no energy whatsoever and she hurt like crazy; it's felt like the flu only much, much worse it only lasted about 36 hours altogether on 26Sep2021. It's very uncomfortable. She was in a lot of pain. She would have gone to the hospital because it felt so bad. She just took some Tylenol finally she didn't like Tylenol it didn't work very well but she did take some; she fell asleep afterwards and so she really didn't know if it helped or not. The patient had head-ache. She finally took some Tylenol (captured as suspect) that was the only treatment that she, you know, she tried to do something about the aches and pains and the muscle pain and well mostly muscle pain and with headache. She felt asleep she have spent yesterday she was trying very, very hard to sleep through it because it was very uncomfortable. It wasn't life threatening but it was very uncomfortable, and she was worried that it would a last long time but it sure did not. The patient felt so wretched on 26Sep2021. Outcome of the events was recovered on an unspecified date in Sep2021.  Follow-up attempts completed. No further information expected.
Headache, Myalgia, Fever, CHILLS/FATIGUE Narrative:
Headaches for two weeks after injection; Tinnitus,  depression,  and red itchy rash near injection site.
fever; chills; nausea; headache; fatigue; had a local reaction of a "patch of inflammation, redness, burning sensation- similar to a 2nd degree burn."; had a local reaction of a "patch of inflammation, redness, burning sensation- similar to a 2nd degree burn."; had a local reaction of a "patch of inflammation, redness, burning sensation- similar to a 2nd degree burn."; This is a spontaneous report from a contactable physician (patient). A 64-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot/batch number not reported), via an unspecified route of administration on 19Dec2020 at a single dose for Covid-19 immunization. Medical history included pneumonia from 03Aug2020 to 08Aug2020. Concomitant medications were not reported. Patient had the first COVID-19 vaccine dose on 19Dec2020. Patient said he had a "pretty strong reaction" of fever, chills, nausea, headache, fatigue in Dec2020. Felt ill until day 2, started feeling better on day 3. Patient also had a local reaction of a "patch of inflammation, redness, burning sensation- similar to a 2nd degree burn" in Dec2020. Patient also mentioned he had his blood work last 30Dec2020 and confirmed he has IgG antibodies. Patient then asked "I want to get the second dose, is it okay to get the vaccine?" The outcome of the events 'fever, chills, nausea, headache, fatigue' was recovering while unknown for the other events.  Information about Lot/Batch number has been requested.
THE IPV AND MMRV WERE ADMINISTERED ON THE LEFT ANTERIOR THIGH.  SURROUNDING ERYTHEMA DEVELOPED WHICH INITIALLY FORMED A RAISED PLAQUE.  OVER 5 DAYS, THE LESION DECREASED IN SIZE AND WAS NO LONGER RAISED.  THE LESION WAS ITCHY AND HAD ASSOCIATED SCALINESS.  CARETAKERS APPLIED HYDROCORTISONE CREAM WHICH DECREASED THE ITCHINESS AND SIZE OF THE LESION. NO ABSCESS FORMATION. NO INGUINAL LYMPHADENOPATHY.  NO FEVER.
Within 12-24 hours post 7th anthrax vax, the pt noted an onset of mild erythema, swelling, tenderness in an area of 3cm x 4cm around the injection site. Similar reaction occurred with 6th shot but not with any others.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old male patient received BNT162b2 (BNT162B2), on 07Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 59 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 01May2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: SYNTHROID.  The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: testing negative on day 6; Positive, notes: Tested positive for Covid on day 10; Positive. Therapeutic measures were taken as a result of covid-19.  Clinical course: The patient received treatment for covid-19, treatment start date: 04may2022, treatment stop date: 08may2022. Patient took medication in 2 weeks and had no known allergies. Patient experienced runny nose sneezing on 13May2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
The week of 1/18/2021 The patient complained of Abdominal pain and called off work (we are also her employer) She was seen for constipation on 1/20/2021.   Employee returned to work on 1/25/2021 Had occasional episodes during work where she would sweat and become tired but would rest until she felt better. On the Night of 1/27/2021 she was feeling fine no issues, later in the shift a co worker found her unresponsive, CPR was initiated but unsuccessful.
Vaccinated in incorrect site; Red mark on site of injection; This spontaneous case was reported by a nurse and describes the occurrence of INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Vaccinated in incorrect site) and VACCINATION SITE ERYTHEMA (Red mark on site of injection) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. no provided) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no reported medical history).    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2021, the patient experienced INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Vaccinated in incorrect site) and VACCINATION SITE ERYTHEMA (Red mark on site of injection). On 01-Mar-2021, INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Vaccinated in incorrect site) had resolved. At the time of the report, VACCINATION SITE ERYTHEMA (Red mark on site of injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.  Based on the current available information and temporal association between the use of the product and the start date of the event of vaccination site erythema, a causal relationship cannot be excluded. Very limited information regarding this event: inappropriate route of vaccination, has been provided at this time. Further information has been requested.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event of vaccination site erythema, a causal relationship cannot be excluded. Very limited information regarding this event: inappropriate route of vaccination, has been provided at this time. Further information has been requested.
One week after receiving the vaccine, I noticed a rash at the injection site.  The rash has continued to spread down my arm.  It is red, burning, and sore to the touch.  I contacted my primary care provider, who prescribed a topical steroid.  I have taken photos of the rash since it started.  It has not improved and continues to spread.
a woman that was in her 70s that managed to get GARDASIL 9; No additional AE information reported.; This spontaneous report was received from a consumer and refers to a female patient of 70s (also reported as 70-80 years old).  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On an unknown date, the patient started therapy with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered for prophylaxis (dose, strength, lot #, expiry date, and route of administration were not provided) in her 70s (product administered to patient of inappropriate age) and she was doing well. No additional adverse event information reported. No product quality complaint reported.
Patient called 9/21/2020 saying she experienced trouble breathing and fatigue right away following immunization administration.
This spontaneous report was received from a registered nurse regarding an unspecified patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concomitant medications were not provided. On an unknown date, the patient was vaccinated with a dose #1 of CERVARIX (dose, route, lot # and expiration date were not reported). On an unknown date, the patient was vaccinated with a dose #2 of GARDASIL (dose, route, lot # and expiration date were not reported). On an unknown date, the patient was vaccinated with a dose #3 of CERVARIX (dose #3, dose, route, lot # and expiration date were not reported). There was no adverse effect reported. Additional information has been requested.
Member is experiencing redness, swelling, intermittent light sensitivity, and blurred vision in LEFT eye approx 9 hours after vaccination. Treatment to date includes opthalmic antibiotics and steriod drops (G.E. Polymyxin B/TMP and Tobradex).
This is a spontaneous report from a contactable consumer (parent). A 35-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: Unknown), via an unspecified route on 25 May 2021 (at the age of 35-years) as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On unspecified date, the patient experienced initially visual hallucination, struggling with brain fog and was unable to do her work. Reporter explained it was difficult for her daughter who an attorney and had to supervise people. She added her brain fog was worse yesterday where it "got the point she is having difficulty speaking fluently". Reporter stated that her daughter was crying and has been dealing with this for 3 days and she was unable to do her work because of the brain fog. Her daughter was unable to pronounce some words due to the brain fog. Her daughter doesn't want the second dose. Her daughter was scheduled to get the second dose on 10Jun2021. She didn't get the second dose because she was scared. The outcome of events was unknown. Information on the lot/batch number has been requested.
The symptoms began 21 days ago. The symptoms are reported as being mild. soft mass on both thighs x 21 days.  Per grandmother getting smaller. No redness, afebrile, mobile
Patient was given a 7th dose of DTaP by age 4yr.    Patient had history of 2 invalid doses previously.  No adverse outcomes that we are aware of at this time.
This spontaneous report was received from a physician's assistance regarding a patient of unknown demographics. No concurrent condition and historical medication was reported. On 04-APR-2015, the patient was vaccinated with expired dose of M-M-R II (lot # J003787, expiration date 28-MAR-2015). No adverse event was reported. No product quality complaint was involved. The outcome of expired product administered was unknown. Causality between event and M-M-R II was unknown. Additional information has been requested.
Severe twitching and jerking of neck hands and head. And trouble breathing with chest tightness
This spontaneous report as received from a nurse refers to multiple unspecified patients of unknown age and gender. The patients' current conditions, medical history and concomitant medications were not reported. On unspecified dates, the patients were vaccinated with improperly stored GARDASIL 9 lot # N000326, expiration date 14-OCT-2019, for prophylaxis. The vaccine was exposed to 32 degree Fahrenheit to 35 degree Fahrenheit for 40 minutes. There was a previous temperature excursion at 32 degree Fahrenheit to 35 degree Fahrenheit for 3 hours 10 minutes. Digital data logger was involved. No adverse effects were reported. There was no product quality complaint (PQC) involved. This is one of the several reports received from same reporter. Sender's Comments: US-009507513-1708USA005627: US-009507513-1708USA005628: US-009507513-1708USA005626.
pt recvd vax 27MAY93 & 4JUN93 pt devel t103.6 & was not walking as well as prev; pt would take a step & fall down; seen by MD & was given Ibuprofen;
Itchy, warm & red rash developed 1 week after injection. Warm to the touch. Cold compress helped reduce redness and inflammation.
Expired vaccine used; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 10-May-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided by the reporter No treatment medications were provided by the reporter.
I21.4 ACUTE NON ST ELEVATION MI 4/19/2021 ACUTE MYELOID LEUKEMIA I21.4 ACUTE NON ST ELEVATION MI 4/19/2021 ACUTE MYELOID LEUKEMIA
Patient's arm red and swollen at injection site. Complained of tingling sensation throughout the arm.
This spontaneous report as received from a other health professional refers to a patient of unknown age with medication dilution. On 07-AUG-2017 the patient was vaccinated with M-M-R II for prophylaxis. Other suspect therapies included sodium chloride (manufacturer unknown). On an unknown date the patient experienced product preparation error and no adverse event. For sodium chloride (manufacturer unknown), the lot number is not available and the serial number is not available.
Flu like symptoms; This case was reported by a other health professional via call center representative and described the occurrence of influenza-like symptoms in a 22-year-old female patient who received Rabies NVS (RabAvert) (batch number ARBA651B, expiry date 20th March 2023) for prophylaxis.   Co-suspect products included LIVE VARICELLA VIRUS VACCINE (CHICKEN POX VACCINE) for prophylaxis.   On 23rd June 2020, the patient received the 2nd dose of RabAvert. On 22nd June 2020, the patient received CHICKEN POX VACCINE. On an unknown date, less than 3 weeks after receiving RabAvert, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was unknown.   It was unknown if the reporter considered the influenza-like symptoms to be related to RabAvert.  Additional details were provided as follows: The reporter stated that, the patient received pre-exposure schedule for Rabavert and experienced flu-like symptoms. The patient received  dose of a chicken pox vaccine just the day before receiving Rabavert 2nd dose. It was unknown if the reporter considered the influenza-like symptoms to be related to Chicken pox vaccine. The reporter consented to follow up.
note sent from parents reporting that pt had a vision problem & hearing difficulty p/vax on 30OCT, recovered w/in min;
Chest pain, upper back pain, shortness of breath, O2 at 90% on room air, pain radiating from injection site down arm, headache, pain down left side of neck, nausea, UTI, rash
Patient developed R ear high pitch ringing and muffled sound the morning after receiving Moderna booster, 7am.    no h/o tinnitus or ear issues in the past.
pt recv vax 21AUG97 2PM that evening approx 6Pm started running high fever, vomiting, trouble breathing;came in 130PM 22AUg97 given Ventolin tx w/relief color better, breathing better;rx given for prelone & ventolin syrup;Phenergan
Localized redness, edema, and itching at injection site. (4x4cm)
Shingrix 50MCG Inj(IM)SNGDSE VL10pk  Shot #1 received on 9/15/20, Shot #2 on 12/1/20 at 3:00pm, at 2:00am got a headache, took Tylenol and about 2:10 nausea and threw up several times, again at 7:00am threw up, headache lasted until about 8pm 12/2/20.
Pain in arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain in arm) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Apr-2021, the patient experienced PAIN IN EXTREMITY (Pain in arm). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Pain in arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were provided.
pt recvd vax; w/in 30 mins exp fever, myalgia, rash on forehead, n,v,d;
12 days later I developed hives on my back, left arm and neck and my right foot and shin. They lasted for 10 days.